Diffusion Pharmaceuticals Inc. (DFFN): Price and Financial Metrics
GET POWR RATINGS... FREE!
DFFN Stock Price Chart Interactive Chart >
DFFN Price/Volume Stats
| Current price | $6.15 | 52-week high | $19.80 |
| Prev. close | $6.23 | 52-week low | $4.64 |
| Day low | $6.15 | Volume | 3,420 |
| Day high | $6.40 | Avg. volume | 9,928 |
| 50-day MA | $5.96 | Dividend yield | N/A |
| 200-day MA | $6.43 | Market Cap | 12.54M |
Diffusion Pharmaceuticals Inc. (DFFN) Company Bio
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. The company is based in Charlottesville, Virginia.
Latest DFFN News From Around the Web
Below are the latest news stories about DIFFUSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DFFN as an investment opportunity.
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special OpportunitiesLifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting |
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-DealingClosing Dates of LifeSci-led Mergers Closing Dates of LifeSci-led Mergers Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies participating in review processLifeSci invited to participate in review process on same terms as all other bidders following submission of client’s unsolicited offer, but LifeSci instead chose to launch a proxy contest against our high |
DFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23…By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating Strategic Opportunities On November 14, 2022, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) provided an update for its previously announced evaluation of strategic opportunities, which may include a sale, merger, divestiture, recapitalization, or other strategic transaction. Since announcing its |
LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion PharmaceuticalsSets the Record Straight on Diffusion’s Misleading Narrative and Raises Concerns about a Troubling Pattern of Entrenchment and Lack of Accountability on the Board Has Nominated a Slate of Highly Qualified Directors NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- LifeSci Special Opportunities Master Fund Ltd. (“LifeSci Special Opportunities” or “we”), the holder of 96,976 shares of common stock of Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”) (NASDAQ: DFFN), or approximately 4.8% of t |
Diffusion Pharmaceuticals GAAP EPS of -$1.37 beats by $0.69Diffusion Pharmaceuticals press release (DFFN): Q3 GAAP EPS of -$1.37 beats by $0.69.As of September 30, 2022, Diffusion had $25.9M in cash, cash equivalents, and marketable… |
DFFN Price Returns
| 1-mo | 9.82% |
| 3-mo | 32.54% |
| 6-mo | -10.35% |
| 1-year | -56.55% |
| 3-year | -72.11% |
| 5-year | -98.67% |
| YTD | 21.61% |
| 2022 | -66.84% |
| 2021 | -61.64% |
| 2020 | 72.56% |
| 2019 | -76.85% |
| 2018 | -88.76% |
Loading social stream, please wait...